Description:

Chemoradiotherapy of Capecitabine With or Without Oxaliplatin Versus Cisplatin-5-FU for Esophageal Squamous Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT02025036

Link:

https://clinicaltrials.gov/show/NCT02025036

Keywords:
Versions (1) ▾
  1. 7/10/19
Copyright Holder:
See clinicaltrials.gov
Uploaded on:

July 10, 2019

DOI:
No DOI assigned. To request one please log in.
License:
Creative Commons BY 4.0
Model comments:

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for:

Item comments for:

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Stage III Esophageal Squamous Cell Carcinoma NCT02025036

Details

Eligibility Stage III Esophageal Squamous Cell Carcinoma NCT02025036

Inclusion Criteria
age 45-75years old
histologically proven squamous cell carcinoma of the esophagus
the tumor was in t2-4n0-1m0
the patients have not received the surgery or chemo-radiotherapy.
hb≥80g/l, absolute neutrophil count ≥1.5×109/l, plt≥90×109/l,
alt、ast≤2.5*n,cr≤1.5*n.
performance status score 0-2
Exclusion Criteria
pregnant, lactating women
oxaliplatin or fluorouracil allergy or metabolic disorders
radiotherapy contraindications
history of organ transplantation
brain metastasis
the peripheral nervous system disorders
severe infection
oral capecitabine who have difficulty with,such as dysphagia,the activities of digestive ulcer, gastrointestinal bleeding
severe chronic diseases, such as, hepatopathy, nephropathy, respiratory disease,high blood pressure, diabetes.
other malignant tumor in recent 5 years.
Back to the top of the page